BIOmarker Driven Trial of VEGFR2 Inhibitor in Advanced Sarcoma
Status:
Recruiting
Trial end date:
2022-05-25
Target enrollment:
Participant gender:
Summary
The aim of this study is to evaluate the efficacy and safety of Apatinib monotherapy for
relapsed or refractory advanced bone and soft tissue sarcoma with VEGFR-2 (KDR) 604A>G
polymorphism as predictive biomarker